Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411249 · ClinicalTrials.gov registry record · Phase 4
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
A Phase 4 study of Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06411249 is a Phase 4 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 350 participants, roughly in line with the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The trial reports 20 study locations across 4 states.
The verdict
NCT06411249, a Phase 4 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
Conditions Studied
Interventions
- DRUG Belimumab (GSK1550188)
Study Locations (20)
California
- GSK Investigational Site - Covina
- GSK Investigational Site - Fontana
- GSK Investigational Site - Fullerton
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Mission Hills
- GSK Investigational Site - San Diego
- GSK Investigational Site - Temecula
- GSK Investigational Site - Tujunga
- GSK Investigational Site - Van Nuys
- GSK Investigational Site - Van Nuys
- GSK Investigational Site - Whittier
Florida
- GSK Investigational Site - Aventura
- GSK Investigational Site - Clearwater
- GSK Investigational Site - Miami
- GSK Investigational Site - Tamarac
Arizona
- GSK Investigational Site - Flagstaff
- GSK Investigational Site - Mesa
- GSK Investigational Site - Tucson
Alabama
- GSK Investigational Site - Anniston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-06-06 |
| Est. Completion | 2029-05-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06411249
The ClinicalTrials.gov registry entry for NCT06411249 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Belimumab (GSK1550188) is the first listed.
NCT06411249 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06411249 about?
NCT06411249 is a clinical study titled "A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)". This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
What is the current status of trial NCT06411249?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2024-06-06. Estimated completion is 2029-05-29.
What conditions does trial NCT06411249 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT06411249?
The interventions under investigation include: Belimumab (GSK1550188) (DRUG).
Who is sponsoring clinical trial NCT06411249?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06411249 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of the Herpes Zoster Subunit Vaccine in Lupus
RECRUITING · Phase 4
-
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
RECRUITING · Phase 4
-
Belimumab Assessment of Safety in SLE
COMPLETED · Phase 4
-
Lupus Atherosclerosis Prevention Study
COMPLETED · Phase 4
-
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
COMPLETED · Phase 4
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.